In the first case, TAT was fused to a peptide derived from the VHL tumor suppressor gene that inhibits insulin-like growth factor-I receptor (IGF-IR) signaling in renal cell carcinomas (RCC) [33,52,54]. This evidence concerns the gene IGF1R and renal cell carcinoma.